Condition
Myelodysplastic Syndrome Acute Myeloid Leukemia
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Recruiting2
Withdrawn1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07719348Phase 1Not Yet Recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT06372717Phase 1Recruiting
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
NCT05211570Phase 1Recruiting
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT04361058Phase 1Withdrawn
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Showing all 4 trials